The May special focus issue of the Journal of Cardiac Failure brings together leading voices in amyloidosis, cardiac sarcoidosis, myocarditis, and inflammatory cardiomyopathies to examine where the field stands today and where it is heading next. On this month’s episode of the Heart Failure Beat, guest editors Drs. Nisha A. Gilotra, Emer Joyce, and Mathew Maurer discussed the diagnostic challenges, therapeutic breakthroughs, and collaborative care models reshaping the future of these diseases.
Cardiomyopathies – A Diagnostic Odyssey
One of the central themes throughout the episode was the “diagnostic odyssey” many patients still experience. Dr. Joyce explained that these diseases often require “a high index of suspicion,” along with the integration of cardiac and extracardiac findings, advanced imaging, pathology, and multidisciplinary collaboration before a diagnosis is finally made.
Dr. Maurer highlighted how the field of amyloidosis has changed dramatically in recent years due to non-biopsy diagnostic approaches and emerging therapies. “The therapies really did change the landscape dramatically,” he explained, emphasizing that earlier diagnosis leads to significantly better outcomes.
More Precise Phenotyping and Targeted Therapies Needed
The episode also explored how inflammatory cardiomyopathies remain highly heterogeneous diseases that require more precise phenotyping and targeted therapies. Dr. Gilotra discussed the growing movement away from broad immunosuppression toward mechanism-based treatment strategies informed by translational science and clinical research.
Multidisciplinary Care is Critical
Another major focus was the importance of multidisciplinary care and education. The guests described how collaboration among cardiologists, pulmonologists, neurologists, orthopedists, pathologists, and imaging specialists is increasingly essential for identifying these diseases earlier.
The discussion concluded with optimism for the next generation of clinicians and researchers entering the field. Dr. Joyce described seeing trainees gain confidence in caring for patients with these conditions as “a new dawn” - not only for the clinicians themselves, but for patients who have long struggled to find recognition and expertise for their disease.
🎧 Listen now to this episode.
Disclaimer:
The opinions and perspectives expressed in this episode are those of the individual guests and hosts and do not necessarily reflect the official views of the Heart Failure Society of America (HFSA). This discussion is intended for educational purposes only and does not constitute medical advice or an endorsement of any specific pharmaceutical product or therapy. HFSA does not endorse one medication over another. Patients should consult their healthcare professionals for individualized evaluation and treatment decisions.